

# Nicholas Finer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8362952/publications.pdf>

Version: 2024-02-01

193  
papers

12,266  
citations

26567

56  
h-index

26548

107  
g-index

217  
all docs

217  
docs citations

217  
times ranked

12719  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2009, 374, 1606-1616.	6.3	931
2	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. <i>New England Journal of Medicine</i> , 2010, 363, 905-917.	13.9	791
3	Effect of sibutramine on weight maintenance after weight loss: a randomised trial. <i>Lancet, The</i> , 2000, 356, 2119-2125.	6.3	790
4	Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. <i>Lancet, The</i> , 2006, 368, 1660-1672.	6.3	722
5	Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. <i>International Journal of Obesity</i> , 2012, 36, 843-854.	1.6	532
6	Obesity surgery: Evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2005, 19, 200-221.	1.3	359
7	Redefining Type 2 diabetes: 'Diabesity' or 'Obesity Dependent Diabetes Mellitus'?. <i>Obesity Reviews</i> , 2000, 1, 57-59.	3.1	348
8	Management of Obesity in Adults: European Clinical Practice Guidelines. <i>Obesity Facts</i> , 2008, 1, 106-116.	1.6	320
9	One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. <i>International Journal of Obesity</i> , 2000, 24, 306-313.	1.6	268
10	Differential Effects of Laparoscopic Sleeve Gastrectomy and Laparoscopic Gastric Bypass on Appetite, Circulating Acyl-ghrelin, Peptide YY3-36 and Active GLP-1 Levels in Non-diabetic Humans. <i>Obesity Surgery</i> , 2014, 24, 241-252.	1.1	222
11	Prevalence, Pathophysiology, Health Consequences and Treatment Options of Obesity in the Elderly: A Guideline. <i>Obesity Facts</i> , 2012, 5, 460-483.	1.6	212
12	A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. <i>American Journal of Medicine</i> , 2002, 112, 348-354.	0.6	193
13	Inter-disciplinary European guidelines on surgery of severe obesity. <i>International Journal of Obesity</i> , 2007, 31, 569-577.	1.6	184
14	Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. <i>British Journal of General Practice</i> , 2008, 58, 548-554.	0.7	173
15	Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 105-112.	2.2	171
16	Interdisciplinary European Guidelines for Surgery for Severe (Morbid) Obesity. <i>Obesity Surgery</i> , 2007, 17, 260-270.	1.1	157
17	Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. <i>Obesity Reviews</i> , 2016, 17, 1001-1011.	3.1	152
18	Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. <i>European Heart Journal</i> , 2010, 31, 3063-3072.	1.0	148

#	ARTICLE	IF	CITATIONS
19	Tamoxifen-Induced Anorexia Is Associated With Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA. <i>Diabetes</i> , 2006, 55, 1327-1336.	0.3	143
20	Interdisciplinary European Guidelines on Surgery of Severe Obesity. <i>Obesity Facts</i> , 2008, 1, 52-59.	1.6	139
21	Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. <i>International Journal of Obesity</i> , 2014, 38, 689-697.	1.6	138
22	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2012, 30, 1047-1055.	0.3	134
23	Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. <i>European Heart Journal</i> , 2007, 28, 2915-2923.	1.0	128
24	Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 523-530.	2.2	125
25	Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 755-761.	2.2	119
26	Childhood Obesity and Vascular Phenotypes. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2643-2650.	1.2	117
27	Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. <i>Breast</i> , 2003, 12, 290-293.	0.9	110
28	A new evidence-based model for weight management in primary care: the Counterweight Programme. <i>Journal of Human Nutrition and Dietetics</i> , 2004, 17, 191-208.	1.3	108
29	Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 1484-1491.	1.3	108
30	The metabolic profile of early Huntington's disease- a combined human and transgenic mouse study. <i>Experimental Neurology</i> , 2008, 210, 691-698.	2.0	99
31	COVID-19 and obesity. <i>Clinical Obesity</i> , 2020, 10, e12365.	1.1	96
32	Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. <i>International Journal of Obesity</i> , 2001, 25, 496-501.	1.6	94
33	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1427-1440.	0.3	86
34	Plasma amino acids and insulin levels in obesity: Response to carbohydrate intake and tryptophan supplements. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 672-676.	1.5	84
35	The impact of a health professional recommendation on weight loss attempts in overweight and obese British adults: a cross-sectional analysis. <i>BMJ Open</i> , 2013, 3, e003693.	0.8	82
36	Adipose and Height Growth Through Childhood and Blood Pressure Status in a Large Prospective Cohort Study. <i>Hypertension</i> , 2012, 59, 919-925.	1.3	81

#	ARTICLE	IF	CITATIONS
37	Periodontal complications with obesity. <i>Periodontology</i> 2000, 2018, 78, 98-128.	6.3	81
38	Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. <i>British Journal of General Practice</i> , 2013, 63, e115-e124.	0.7	79
39	Pharmacotherapy for obesity: novel agents and paradigms. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 135-148.	1.1	78
40	Is obesity a disease?. <i>International Journal of Obesity</i> , 2001, 25, 1401-1404.	1.6	77
41	Current approaches to obesity management in UK Primary Care: the Counterweight Programme. <i>Journal of Human Nutrition and Dietetics</i> , 2004, 17, 183-190.	1.3	76
42	Cardiovascular effects of phentermine and topiramate. <i>Journal of Hypertension</i> , 2014, 32, 1178-1188.	0.3	76
43	Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 648-654.	5.5	76
44	Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. <i>Diabetic Medicine</i> , 2018, 35, 360-367.	1.2	75
45	Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue. <i>European Journal of Endocrinology</i> , 2012, 166, 951-955.	1.9	73
46	Drug interventions for the treatment of obesity in children and adolescents. <i>The Cochrane Library</i> , 2020, 2020, CD012436.	1.5	73
47	Reported appetite, taste and smell changes following Roux-en-Y gastric bypass and sleeve gastrectomy: Effect of gender, type 2 diabetes and relationship to post-operative weight loss. <i>Appetite</i> , 2016, 107, 93-105.	1.8	73
48	Validation of a Quantitative Magnetic Resonance Method for Measuring Human Body Composition. <i>Obesity</i> , 2008, 16, 191-198.	1.5	72
49	Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). <i>American Journal of Clinical Nutrition</i> , 2003, 78, 209-214.	2.2	69
50	Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1109-1115.	1.5	68
51	Long-term cost-effectiveness of weight management in primary care. <i>International Journal of Clinical Practice</i> , 2010, 64, 775-783.	0.8	65
52	Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2010, 99, 673-678.	0.7	62
53	Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. <i>Diabetologia</i> , 2012, 55, 2348-2355.	2.9	62
54	The effects of Ramadan fasting on activity and energy expenditure. <i>American Journal of Clinical Nutrition</i> , 2018, 107, 54-61.	2.2	61

#	ARTICLE	IF	CITATIONS
55	Sibutramine: its mode of action and efficacy. <i>International Journal of Obesity</i> , 2002, 26, S29-S33.	1.6	59
56	Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 206-213.	2.2	59
57	The comparative effects of bariatric surgery on weight and type 2 diabetes. <i>Obesity Surgery</i> , 2007, 17, 1248-1256.	1.1	59
58	Psychiatric co-morbidities in patients attending specialist obesity services in the UK. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 317-325.	0.2	58
59	Oxidant Stress in Healthy Normal-weight, Overweight, and Obese Individuals. <i>Obesity</i> , 2009, 17, 460-466.	1.5	58
60	Empowering primary care to tackle the obesity epidemic: the Counterweight Programme. <i>European Journal of Clinical Nutrition</i> , 2005, 59, S93-S101.	1.3	56
61	Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults. <i>Circulation</i> , 2018, 138, 2187-2201.	1.6	55
62	Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals. <i>PLoS ONE</i> , 2013, 8, e59121.	1.1	54
63	Pharmacotherapy of obesity. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2002, 16, 717-742.	2.2	47
64	New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects. <i>Canadian Journal of Cardiology</i> , 2015, 31, 142-152.	0.8	47
65	Early vascular damage from smoking and alcohol in teenage years: the ALSPAC study. <i>European Heart Journal</i> , 2019, 40, 345-353.	1.0	46
66	Two cases of Wegener's granulomatosis involving the pituitary. <i>Clinical Endocrinology</i> , 1995, 42, 323-328.	1.2	45
67	Association between fat mass through adolescence and arterial stiffness: a population-based study from The Avon Longitudinal Study of Parents and Children. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 474-481.	2.7	45
68	Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight loss outcomes. <i>Obesity</i> , 2014, 22, 2137-2146.	1.5	44
69	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1441-1455.	0.3	44
70	Medical consequences of obesity. <i>Medicine</i> , 2015, 43, 88-93.	0.2	43
71	The composition of lunch determines afternoon plasma tryptophan ratios in humans. <i>Journal of Neural Transmission</i> , 1986, 65, 211-217.	1.4	42
72	NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity. <i>Obesity Surgery</i> , 2016, 26, 649-659.	1.1	40

#	ARTICLE	IF	CITATIONS
73	Commissioning guidance for weight assessment and management in adults and children with severe complex obesity. <i>Obesity Reviews</i> , 2018, 19, 14-27.	3.1	39
74	Low-calorie Diets and Sustained Weight Loss. <i>Obesity</i> , 2001, 9, 290S-294S.	4.0	37
75	Predictors of programme adherence and weight loss in women in an obesity programme using meal replacements. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 439-447.	2.2	35
76	Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2015, 33, 425-434.	0.3	34
77	Present and future pharmacological approaches. <i>British Medical Bulletin</i> , 1997, 53, 409-432.	2.7	33
78	Novel insights into maladaptive behaviours in Prader-Willi syndrome: serendipitous findings from an open trial of vagus nerve stimulation. <i>Journal of Intellectual Disability Research</i> , 2016, 60, 149-155.	1.2	33
79	Criteria for EASO-Collaborating Centres for Obesity Management. <i>Obesity Facts</i> , 2011, 4, 329-333.	1.6	32
80	Changes in risk factors for cardiovascular disease with body fat loss in obese women. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 379-387.	2.2	31
81	Management: Part II—Drugs. <i>BMJ: British Medical Journal</i> , 2006, 333, 794-797.	2.4	31
82	Obesity. <i>Clinical Medicine</i> , 2003, 3, 23-27.	0.8	30
83	Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the 'Darwin study'. <i>Diabetologia</i> , 2005, 48, 222-229.	2.9	30
84	Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 498-505.	2.2	28
85	Selenium Supplementation and Exercise: Effect on Oxidant Stress in Overweight Adults. <i>Obesity</i> , 2012, 20, 794-801.	1.5	28
86	RESPONSES OF NEUROHYPOPHYSIAL PEPTIDES TO HYPERTONIC SALINE AND INSULIN-INDUCED HYPOGLYCAEMIA IN MAN. <i>Clinical Endocrinology</i> , 1986, 24, 97-105.	1.2	27
87	Feasibility and Impact of a Combined Supervised Exercise and Nutritional-Behavioral Intervention following Bariatric Surgery: A Pilot Study. <i>Journal of Obesity</i> , 2015, 2015, 1-12.	1.1	26
88	Growth hormone (GH) replacement therapy in GH deficient adults: Predictors of one-year metabolic and clinical response. <i>Growth Hormone and IGF Research</i> , 2007, 17, 67-76.	0.5	25
89	Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance. <i>Obesity</i> , 2011, 19, 1404-1414.	1.5	25
90	Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 656-662.	1.1	25

#	ARTICLE	IF	CITATIONS
91	Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients. <i>International Journal of Obesity</i> , 2014, 38, 432-437.	1.6	24
92	Pregnancy in a woman with premature ovarian failure. <i>Postgraduate Medical Journal</i> , 1985, 61, 1079-1080.	0.9	23
93	Drug therapy after very-low-calorie diets. <i>American Journal of Clinical Nutrition</i> , 1992, 56, 195S-198S.	2.2	23
94	Blood pressure changes associated with sibutramine and weight management – an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT)*. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 239-250.	2.2	23
95	Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3746-3753.	4.3	23
96	Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. <i>International Journal of Obesity</i> , 2014, 38, 1165-1171.	1.6	23
97	Reply: Is obesity a disease?. <i>International Journal of Obesity</i> , 2001, 25, 1405-1406.	1.6	22
98	Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 393-402.	0.8	21
99	Medical consequences of obesity. <i>Medicine</i> , 2011, 39, 18-23.	0.2	21
100	Metabolic rate after massive weight loss in human obesity. <i>Clinical Science</i> , 1986, 70, 395-398.	1.8	20
101	Engaging patients, clinicians and health funders in weight management: the Counterweight Programme. <i>Family Practice</i> , 2008, 25, i79-i86.	0.8	20
102	Quantitative Magnetic Resonance (QMR) for Longitudinal Evaluation of Body Composition Changes With Two Dietary Regimens. <i>Obesity</i> , 2010, 18, 391-396.	1.5	20
103	The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change. <i>Obesity Research and Clinical Practice</i> , 2008, 2, 15-27.	0.8	19
104	The implementation of the Counterweight Programme in Scotland, UK. <i>Family Practice</i> , 2012, 29, i139-i144.	0.8	19
105	The Effect of Enkephalin Analogue on Pituitary Hormone Release in Human Obesity. <i>Hormone and Metabolic Research</i> , 1987, 19, 68-70.	0.7	18
106	PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample*. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 1248-1260.	2.2	18
107	Action on obesity: comprehensive care for all. <i>Clinical Medicine</i> , 2013, 13, 4-5.	0.8	18
108	The Impact of Diet-Induced Weight Loss on Biomarkers for Colorectal Cancer: An Exploratory Study (INTERCEPT). <i>Obesity</i> , 2017, 25, S95-S101.	1.5	18

#	ARTICLE	IF	CITATIONS
109	Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 44-54.	2.2	18
110	Impact of Waist Circumference Difference on Health-Care Cost among Overweight and Obese Subjects: The PROCEED Cohort. <i>Value in Health</i> , 2010, 13, 402-410.	0.1	17
111	Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period. <i>Obesity</i> , 2010, 18, 987-994.	1.5	17
112	Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 26-34.	2.2	17
113	Obesity Management in Europe: Current Status and Objectives for the Future. <i>Obesity Facts</i> , 2016, 9, 273-283.	1.6	17
114	Future directions in obesity pharmacotherapy. <i>European Journal of Internal Medicine</i> , 2021, 93, 13-20.	1.0	16
115	Age- and sex-specific effects on weight loss outcomes in a comparison of sleeve gastrectomy and Roux-en-Y gastric bypass: a retrospective cohort study. <i>BMC Obesity</i> , 2014, 1, 12.	3.1	15
116	Pituitary infarction and development of the empty sella syndrome after gastrointestinal haemorrhage. <i>BMJ: British Medical Journal</i> , 1984, 289, 661-662.	2.4	14
117	The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight loss. <i>Eating Behaviors</i> , 2002, 3, 275-284.	1.1	14
118	Drug Treatment of Obesity in Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 93-104.	1.0	14
119	Medical consequences of obesity. <i>Medicine</i> , 2006, 34, 510-514.	0.2	13
120	The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period. <i>BMC Endocrine Disorders</i> , 2010, 10, 3.	0.9	13
121	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1678-1688.	0.3	13
122	The clinical effectiveness of weight loss drugs. <i>Obesity Research and Clinical Practice</i> , 2007, 1, 1-5.	0.8	12
123	MAMMARY GIGANTISM AND D-PENICILLAMINE. <i>Clinical Endocrinology</i> , 1984, 21, 219-222.	1.2	11
124	Rationing joint replacements: Trust's decision seems to be based on prejudice or attributing blame. <i>BMJ: British Medical Journal</i> , 2005, 331, 1472.2.	2.4	11
125	Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. <i>Nutrition and Metabolism</i> , 2009, 6, 42.	1.3	10
126	Pre-pregnancy weight loss in women with obesity requesting removal of their intrauterine contraceptive device in order to conceive: a pilot study of full meal replacement. <i>Clinical Obesity</i> , 2018, 8, 244-249.	1.1	10



#	ARTICLE	IF	CITATIONS
127	Moderate Exercise and Fibrinolytic Potential in Obese Sedentary Men with Metabolic Syndrome. <i>Obesity</i> , 2003, 11, 1333-1338.	4.0	9
128	Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 121-124.	0.6	9
129	Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. <i>Country Review Ukraine</i> , 2005, 7, L32-L38.	0.8	9
130	Obesity in Europe â€œ does anybody care?. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 971-973.	0.9	9
131	Latent Autoimmune Diabetes in Adults Presenting as Diabetes â€œRecurrenceâ€•After Bariatric Surgery: A Case Report. <i>Diabetes Care</i> , 2013, 36, e120-e120.	4.3	9
132	Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. <i>Clinical Obesity</i> , 2015, 5, 245-255.	1.1	9
133	A case of severe anorexia, excessive weight loss and high peptide YY levels after sleeve gastrectomy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 150020.	0.2	9
134	Relation between weight loss and causes of death in patients with cardiovascular disease. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 144-151.	0.6	9
135	Effectiveness and costâ€œeffectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 118-124.	2.2	9
136	<i>Clinical Obesity</i> â€œ a new journal for a new clinical era. <i>Clinical Obesity</i> , 2011, 1, 1-2.	1.1	8
137	Predicting therapeutic weight loss. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 419-420.	2.2	8
138	Prolonged weight loss with dexfenfluramine treatment in obese patients. <i>DiabÃ“te &amp; MÃ©tabolisme</i> , 1987, 13, 598-602.	0.3	8
139	Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. <i>International Journal of Obesity</i> , 2015, 39, 849-857.	1.6	7
140	Direct ophthalmoscopy should be taught to undergraduate medical students. <i>Eye</i> , 2016, 30, 497-497.	1.1	7
141	Editorial is judgment in advance of the facts. <i>BMJ: British Medical Journal</i> , 2010, 340, c1346-c1346.	2.4	7
142	Sibutramine in clinical practice. <i>International Journal of Obesity</i> , 2001, 25, S12-S15.	1.6	6
143	Act now against new NHS competition regulations. <i>BMJ, The</i> , 2013, 346, f1819-f1819.	3.0	6
144	A comprehensive descriptive assessment of obesity related chronic morbidity and estimated annual cost burden from a population-based electronic health record database. <i>Israel Journal of Health Policy Research</i> , 2020, 9, 32.	1.4	6

#	ARTICLE	IF	CITATIONS
145	Interdisciplinary European guidelines on metabolic and bariatric surgery. Gastroenterologie A Hepatologie, 2017, 71, 487-500.	0.0	6
146	Obesity and risk of myocardial infarction: the INTERHEART study. Lancet, The, 2006, 367, 1053.	6.3	5
147	Obesity remains under diagnosed in English hospital in-patients. Obesity Research and Clinical Practice, 2009, 3, 17-20.	0.8	5
148	EFFECTS ON MORTALITY AND MORBIDITY IN OVERWEIGHT/OBESE SUBJECTS: THE SIBUTRAMINE CARDIOVASCULAR OUTCOMES (SCOUT) TRIAL. Journal of the American College of Cardiology, 2010, 55, A141.E1326.	1.2	4
149	Preventing diabetes: a call for concerted national action. Clinical Medicine, 2013, 13, 328-329.	0.8	4
150	Weight loss for patients with obesity and heart failure. European Heart Journal, 2019, 40, 2139-2141.	1.0	4
151	The Cost of Obesity in the United Kingdom. Journal of Medical Economics, 1999, 2, 143-153.	1.0	3
152	Better measures of fat mass " beyond <sc>BMI</sc>. Clinical Obesity, 2012, 2, 65-65.	1.1	3
153	Drug treatment of obesity in the cardiovascular patient. Current Opinion in Cardiology, 2013, 28, 584-591.	0.8	3
154	Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 3, pvw029.	1.4	3
155	Ceftazidime versus aminoglycoside and (ureido)penicillin combination in the empirical treatment of serious infection. Journal of the Royal Society of Medicine, 1992, 85, 530-3.	1.1	3
156	Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine. , 1989, 13 Suppl 2, 91-3.		3
157	Diet and Noradrenaline Induced Thermogenesis in Massive Obesity. Clinical Science, 1983, 65, 23P-23P.	1.8	2
158	Serotonergic System: Therapeutic Implications in Obesity. Acta Clinica Belgica, 1992, 47, 47-51.	0.5	2
159	Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. British Journal of Diabetes and Vascular Disease, 2008, 8, 170-176.	0.6	2
160	Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine. Journal of Obesity, 2011, 2011, 1-8.	1.1	2
161	Outcomes of an adolescent bariatric service. Archives of Disease in Childhood, 2012, 97, A63.1-A63.	1.0	2
162	Jejunioleal bypass: A model for the study of the entero-insular axis. Regulatory Peptides, 1982, 3, 82.	1.9	1

#	ARTICLE	IF	CITATIONS
163	Metergoline as an alternative to bromocriptine in amenorrhoea. <i>European Journal of Endocrinology</i> , 1984, 107, 439-444.	1.9	1
164	Rimonabant in obese patients with type 2 diabetes – Authors' reply. <i>Lancet, The</i> , 2007, 369, 554-555.	6.3	1
165	Drug treatments for obesity. <i>Lancet, The</i> , 2007, 369, 1163.	6.3	1
166	New targets for obesity pharmacotherapy – developing anti-obesity drugs that do not necessarily produce weight loss. <i>Clinical Obesity</i> , 2011, 1, 61-61.	1.1	1
167	Developing a specialist obesity infrastructure: an example from current strategies in England. <i>Clinical Obesity</i> , 2013, 3, 1-2.	1.1	1
168	Weight Management: Approaches. , 2013, , 404-409.		1
169	Comment on Balkau et al. Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. <i>Diabetes Care</i> 2014;37:2108–2113. <i>Diabetes Care</i> , 2014, 37, e265-e265.	4.3	1
170	Obesity and difficult-to-treat arterial hypertension. <i>Clinical Obesity</i> , 2014, 4, 59-60.	1.1	1
171	Can we reconcile the obesity paradox™ with recent cardiovascular outcome trials in diabetes?. <i>Clinical Obesity</i> , 2017, 7, 255-259.	1.1	1
172	The EAES Clinical Practice Guidelines on Obesity Surgery (2005). , 2006, , 213-257.		1
173	Do frequent clinic visits improve diabetic control?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1985, 2, 30-31.	0.2	0
174	Very Low Calorie Diet and Noradrenaline-Induced Thermogenesis in Human Obesity. <i>Clinical Science</i> , 1987, 73, 17P-17P.	0.0	0
175	Prediction of Resting Metabolic Rate in Man by Bio-Impedance Analysis [Bia]. <i>Clinical Science</i> , 1988, 74, 2P-2P.	0.0	0
176	WEIGHT MANAGEMENT   Approaches*. , 1998, , 407-413.		0
177	Drug therapy for management of obesity. <i>Lancet, The</i> , 2001, 357, 1288.	6.3	0
178	Atlas of Obesity and Weight Control. <i>Clinical Endocrinology</i> , 2004, 60, 150-150.	1.2	0
179	Alli: a friend to the overweight. <i>The Prescriber</i> , 2009, 20, 6-6.	0.1	0
180	Counterweight - counter-cost, counter-loss. <i>International Journal of Clinical Practice</i> , 2010, 64, 828-829.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Obesity and pre-diabetes. <i>Clinical Obesity</i> , 2012, 2, 1-2.	1.1	0
182	Fat Chance. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, s20.	5.5	0
183	Obesity and androgens: Masculinity or muscularity?. <i>Clinical Obesity</i> , 2013, 3, 59-61.	1.1	0
184	Sarcopenic obesity: under recognised and over treated?. <i>Clinical Medicine</i> , 2014, 14, 454.	0.8	0
185	Clinical pictures. <i>Clinical Obesity</i> , 2014, 4, 125-126.	1.1	0
186	Clinical obesity comes of age. <i>Clinical Obesity</i> , 2015, 5, 1-1.	1.1	0
187	Response to "Does smoking or alcohol cause early vascular damage in teenage years?". <i>European Heart Journal</i> , 2019, 40, 3497-3497.	1.0	0
188	Letter to the Editor regarding Mocanu et al. Ongoing Inconsistencies in Weight Loss Reporting Following Bariatric Surgery: a Systematic Review. <i>Obesity Surgery</i> <a href="https://doi.org/10.1007/s11695-018-03702-6">https://doi.org/10.1007/s11695-018-03702-6</a> Mocanu. <i>Obesity Surgery</i> , 2019, 29, 1942-1942.	1.1	0
189	Body mass index trajectories among people with obesity and association with mortality: Evidence from a large Israeli database. <i>Obesity Science and Practice</i> , 2021, 7, 148-158.	1.0	0
190	THE EFFECT OF MODERATE EXERCISE ON PLASMINOGEN ACTIVATOR INHIBITOR IN OBESE VS NON OBESE SEDENTARY MALES. <i>Medicine and Science in Sports and Exercise</i> , 2001, 33, S78.	0.2	0
191	Aspartame and its effects on health: Approach seems simplistic in electronic responses to editorial. <i>BMJ: British Medical Journal</i> , 2005, 330, 310.2.	2.4	0
192	The comparative effects of bariatric surgery on weight and type 2 diabetes. <i>Obesity Surgery</i> , 2007, 17, 1248-1256.	1.1	0
193	Prevention and management of obesity: pharmacology. <i>Proceedings of the Nutrition Society</i> , 2000, 59, 413.	0.4	0